Pharmaceutical & Biopharmaceutical Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, Advanced Drug Delivery Products, Over the Counter (OTC) Medicines, Others), By Service (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 14.23 Billion
CAGR (2026-2031)	6.21%
Fastest Growing Segment	Active Pharmaceutical Ingredients (API)
Largest Market	North America
Market Size (2031)	USD 20.43 Billion

Market Overview

The Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market is projected to grow from USD 14.23 Billion in 2025 to USD 20.43 Billion by 2031 at a 6.21% CAGR. Pharmaceutical and biopharmaceutical contract manufacturing involves outsourcing various stages of drug production, encompassing development, manufacturing, and packaging, to specialized third-party organizations. This strategic engagement allows pharmaceutical companies to leverage external expertise, infrastructure, and technology, thereby focusing on core competencies like research and development. The market's growth is primarily supported by drivers such as the increasing complexity of drug pipelines, particularly for biologics and advanced therapies, the need for cost efficiency and resource optimization, and the demand for specialized manufacturing capabilities. According to the Drug, Chemical & Associated Technologies Association (DCAT), in March 2025, over 23,000 molecules were in active development across preclinical to Phase 3 stages, indicating substantial demand for outsourced manufacturing services.

A significant challenge that could impede market expansion is the ongoing labor shortages and skills gaps within the pharmaceutical manufacturing sector. This scarcity of qualified personnel limits production capacities for contract manufacturers, affecting their ability to meet growing client demands and innovate effectively. The market navigates these operational complexities while ensuring stringent regulatory compliance and maintaining high-quality standards.

Key Market Drivers

The rising demand for biologics and advanced therapies represents a significant driver for the global pharmaceutical and biopharmaceutical contract manufacturing market. These complex drug modalities, including bispecific antibodies and antibody-drug conjugates, necessitate specialized manufacturing processes, sophisticated equipment, and distinct expertise that many pharmaceutical and biotechnology companies lack internally. Outsourcing to contract development and manufacturing organizations (CDMOs) allows drug innovators to access these critical capabilities without substantial capital investment in highly specialized facilities or personnel. According to WuXi Biologics, in its annual results reported in March 2026, the company added a record 209 new integrated projects in 2025, with two-thirds involving complex biologics such as bispecifics and ADCs. This highlights the increasing reliance on CDMOs for the production of such intricate therapeutic agents.

The increasing outsourcing by pharmaceutical and biotechnology companies is a fundamental accelerant for market expansion. Companies strategically engage CDMOs to enhance cost efficiency, reduce capital expenditure, and accelerate drug development timelines, allowing them to focus on core competencies like research and innovation. This trend is particularly evident among small and medium-sized biopharma firms that benefit from established manufacturing infrastructure and regulatory expertise provided by contract partners. WuXi Biologics reported that its integrated CRDMO platform supported 945 ongoing integrated biologics programs by the end of 2025. This extensive portfolio underscores the growing strategic reliance on external manufacturing partnerships across the industry. Concurrently, broader investments in manufacturing capacity reinforce market confidence; according to Thermo Fisher Scientific, in April 2025, the company announced a $2 billion investment over the next four years in its U.S. operations, including $1.5 billion in capital expenditures to expand manufacturing.

Download Free Sample Report

Key Market Challenges

The ongoing labor shortages and skills gaps within the pharmaceutical manufacturing sector present a significant impediment to the growth of the global pharmaceutical and biopharmaceutical contract manufacturing market. This scarcity of qualified personnel directly limits the production capacities of contract manufacturers, affecting their ability to scale operations and meet increasing client demands for drug development and manufacturing services.

The lack of a sufficiently skilled workforce directly restrains market expansion by creating operational bottlenecks. According to the National Association of Manufacturers (NAM), in Q3 2025, the average manufacturer in the U.S. reported approximately 4.2% of positions unfilled, with a quarter of manufacturers experiencing vacancy rates exceeding 5%. These persistent gaps in talent, particularly in specialized areas required for complex biologic and advanced therapy production, hinder the rapid ramp-up of new projects and the efficient execution of existing contracts, thereby limiting revenue growth for contract manufacturing organizations.

Key Market Trends

The Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market is experiencing a significant shift through digitalization and artificial intelligence integration in manufacturing. CDMOs are increasingly adopting advanced analytics and AI-powered tools to enhance operational efficiency, improve quality control, and optimize production processes. This technological adoption helps in predicting potential bottlenecks and reducing manufacturing risks across various stages of drug production, from R&D to commercial output. For instance, by early 2025 Lonza implemented AI-driven Process Analytical Technology across primary biologics lines, successfully cutting estimated batch failures by 15 percent. This integration extends to real-time batch tracking and regulatory documentation, fostering greater transparency and accelerating market timelines.

Another prominent trend reshaping the market is the growth of integrated end-to-end service offerings by CDMOs. Pharmaceutical and biopharmaceutical companies are increasingly seeking comprehensive solutions from a single contract partner that can manage the entire drug development and manufacturing lifecycle, from early-stage development through commercialization. This consolidated approach allows clients to streamline complex supply chains, reduce vendor management complexities, and benefit from seamless transitions between development phases. Catalent, for example, is actively shifting towards becoming an end-to-end biologics specialist, with a strategic goal of cutting partner time-to-market by approximately 25% compared to managing fragmented supply chains. Such integrated offerings enhance efficiency and foster deeper, more strategic partnerships in the industry.

Segmental Insights

The Active Pharmaceutical Ingredients (API) segment is experiencing rapid growth within the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, driven by several interconnected factors. Pharmaceutical companies are increasingly outsourcing API production due to the rising complexity of modern drug molecules and advanced therapeutic modalities, which necessitate specialized expertise and sophisticated manufacturing capabilities. Furthermore, stringent global regulatory requirements from bodies such as the FDA and EMA for quality, safety, and supply chain transparency compel manufacturers to partner with experienced contract organizations that can ensure meticulous compliance. This strategic shift allows pharmaceutical firms to reduce operational costs, streamline development, and focus on core drug discovery efforts, thereby accelerating market access for new medicines.

Regional Insights

North America leads the global pharmaceutical and biopharmaceutical contract manufacturing market owing to its highly advanced industry and strong regulatory frameworks. The robust oversight by bodies such as the U.S. Food and Drug Administration (FDA) establishes high quality and safety standards, fostering confidence and a predictable operational environment. The region benefits from substantial research and development investment, particularly in complex biologics and advanced therapies, which necessitates specialized manufacturing expertise. Furthermore, the established presence of major global pharmaceutical companies and extensive outsourcing by these firms further consolidates North America's dominant position, supported by its sophisticated manufacturing infrastructure.

Recent Developments

• In April 2026, Lonza Group AG, a leading contract development and manufacturing organization, announced a funded research collaboration with Simulations Plus, Inc. and the U.S. Food and Drug Administration. The initiative aims to develop and validate a mechanistic, predictive framework for evaluating the in vivo performance of amorphous solid dispersion (ASD) drug products. Lonza is slated to perform experimental work, including advanced in vitro dissolution testing and detailed characterization of various ASD formulation variants. This collaboration illustrates the commitment within the biopharmaceutical contract manufacturing sector to scientific advancements and improved regulatory decision-making for complex oral drug formulations.
• In September 2025, Thermo Fisher Scientific Inc. finalized the acquisition of Sanofi's state-of-the-art sterile fill-finish and packaging facility located in Ridgefield, New Jersey. This strategic expansion significantly bolstered Thermo Fisher's U.S. manufacturing capabilities within its comprehensive pharma services business. The integration of this facility enabled Thermo Fisher to address the increasing demand from pharmaceutical and biotechnology clients for domestic manufacturing capacity, while also continuing the production of therapies for Sanofi. This acquisition further enhanced Thermo Fisher's global sterile fill-finish network, solidifying its role as a key contract development and manufacturing organization.
• In May 2025, China National Pharmaceutical Group Co Ltd (Sinopharm) and Switzerland-headquartered Lonza Group formalized the extension of their joint venture, Suzhou Capsugel Limited, for an additional 20 years. The agreement was signed in the Suzhou Industrial Park, emphasizing the enduring commitment of both companies to the pharmaceutical sector. This renewal reinforced Suzhou Capsugel's position as a leading manufacturer of empty capsules in Asia, substantially contributing to the growth of pharmaceutical manufacturing capabilities within the global contract manufacturing market. The extended partnership is set to foster further cooperation and facilitate the integration of advanced technologies.
• In January 2025, WuXi Biologics, a prominent global contract research, development, and manufacturing organization, entered into a significant research services collaboration agreement with Candid Therapeutics. This partnership was established to advance therapeutic development, with Candid Therapeutics securing global rights to a trispecific antibody. The antibody, developed on WuXi Biologics' advanced WuXiBody™ platform, was in preclinical development and designed for simultaneous targeting of three different antigen sites: BCMA, CD20, and CD19. This collaboration underscores the ongoing innovation and strategic alliances within the biopharmaceutical contract manufacturing market for complex biologic therapies.

Key Market Players

• Jubilant Pharmova Limited
• JRS PHARMA GmbH & Co.
• Boehringer Ingelheim GmbH
• Lonza Group
• Rentschler Biotechnologie GmbH
• Inno Biologics Sdn Bhd
• INCOG BioPharma Services
• Baxter Biopharma Solutions
• Catalent Pharma Solutions
• Kemwell Biopharma Private Limited

By Product Type	By Service	By Region
Active Pharmaceutical Ingredients (API) Finished Dosage Formulation Advanced Drug Delivery Products Over the Counter (OTC) Medicines Others	Pharmaceutical Manufacturing Services Biologics Manufacturing Services Drug Development Services Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Product Type:

• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulation
• Advanced Drug Delivery Products
• Over the Counter (OTC) Medicines
• Others

• Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Service:

• Pharmaceutical Manufacturing Services
• Biologics Manufacturing Services
• Drug Development Services
• Others

• Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE